Acute respiratory dynamics in chronic hypoxemia: Insights to COPD pathogenesis | [Rawal Medical Journal • 2025]

Author(s):

1. Hina Riaz: Departments of Physiology, Dow University of Health Sciences Karachi, Pakistan

2. Javeria Hameed Shaikh: Liaquat University of Medical and Health Science, Jamshoro, Pakistan; Liaquat University of Medical And Health Science, Jamshoro, Pakistan

3. Sabahat Shaikh: Liaquat University of Medical and Health Science, Jamshoro, Pakistan; Liaquat University of Medical And Health Science, Jamshoro, Pakistan

4. Keenjher Rani: Liaquat University of Medical and Health Science, Jamshoro, Pakistan; Liaquat University of Medical And Health Science, Jamshoro, Pakistan

5. Aneesa Khalid: Hussain Memorial Medical College, Lahore, Pakistan

6. Urooj Bhatti: Liaquat University of Medical and Health Science, Jamshoro, Pakistan; Liaquat University of Medical And Health Science, Jamshoro, Pakistan

Abstract:

Objective: This study analyzed the pattern of acute respiratory events in chronic hypoxemia with emphasis on exacerbations of chronic obstructive pulmonary disease (COPD). Methodology: This descriptive observational study was conducted from February 2023 to June 2023 and included 52 COPD patients suffering from chronic hypoxemia. Chronic exacerbations were assessed using Winnipeg Criteria considering Type 1, Type 2 or Type 3. Hospitalization level, calculated as oxygen saturation <90%, comorbidities and the severity of the patient's symptoms, was determined. The treatment outcomes were measured by FEV1 and treatment failures in patients receiving corticosteroids. All quantitative data were analyzed by SPSS version 20 and descriptive and inferential statistics, including chi-square tests and paired t-tests. Results: This study found 16 (30%) of patients with Type 1 exacerbations, 19 (37%) with Type 2 and 17 (33%) with Type 3. Hospitalization indicators were present in 67% and of patients that received oxygen. 33% had an oxygen saturation level lower than 90%. Corticosteroid therapy produced significant increase in FEV1 in 77% of the patients (p<0.05) and reduced the treatment failure in 23% of the patients. Conclusion: This work reinforces the clinical utility of the Winnipeg Criteria in the assessment of COPD and finding their key predicators for hospitalization. Cor-ticosteroid therapy was very effective in improving FEV1 and minimizing the chances of failures during treatment. Early detection of exacerbation patterns is necessary so that proper management and care can be given to reduce adverse clinical outcomes.

Page(s): 314-317

DOI: DOI not available

Published: Journal: Rawal Medical Journal, Volume: 50, Issue: 2, Year: 2025

Keywords:

Chronic Obstructive Pulmonary Disease , Acute exacerbation , corticosteroid therapy , chronic hypoxemia , Winnipeg Criteria

References:

[1] Halpin DM,Criner GJ,Papi A,Singh D,Anzueto A,Martinez FJ .2021 .chronic obstructive pulmonary disease. Am J Resp Crit Care Med, 203 : 24-36.

[2] MacLeod M,Papi A,Contoli M,Beghé B,Celli BR,Wedzicha JA .2021 .Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology, 26 : 532-51.

[3] Rosenwasser Y,Berger I,Loewy ZG .2022 .Therapeutic approaches for chronic obstructive pulmonary disease (COPD) exacerbations. Pathogens, 11 : 1513-7.

[4] Soler-Cataluña JJ,Miravitlles M,Fernández-Villar A,Izquierdo JL,García-Rivero JL,Cosio BG .2023 .Exacerbations in COPD: a personalised approach to care. The Lancet Resp Med, 11 : 224-6.

[5] Ushida K,Shimizu A,Hori S,Yamamoto Y,Momosaki R .2022 .Hospital frailty risk score predicts outcomes in chronic obstructive pulmonary disease exacerbations. Arch Gerontol Geriatrics, 100 : 104658.

[6] Wu L,Lan N,Yang X. .2021 .Effects of empirical glucocorticoid use on severe acute exacerbation of COPD during hospitalization. Int J COPD, 24 : 2419-31.

[7] Galerneau LM,Bailly S,Terzi N,Ruckly S,GarrousteOrgeas M,Cohen Y .2023 .Corticosteroids for severe acute exacerbations of chronic obstructive pulmonary disease in intensive care: From the French OUTCOMEREA cohort. Plos One, 18 : e0284591.

[8] Fekete M,Fazekas-Pongor V,Balazs P,Tarantini S,Nemeth AN,Varga JT .2021 .Role of new digital technologies and telemedicine in pulmonary rehabilitation: Smart devices in the treatment of chronic respiratory diseases. Wiener Klinische Wochenschrift, 133 : 1201-7.

[9] Rochester CL,Alison JA,Carlin B,Jenkins AR,Cox NS,Bauldoff G .2023 .Pulmonary rehabilitation for adults with chronic respiratory disease: an official American Thoracic Society clinical practice guideline. Am J Resp Crit Care Med, 208 : e7-26.

[10] Rodrigues SD,Cunha CM,Soares GM,Silva PL,Silva AR,Goncalves-de-Albuquerque CF .2021 .Mechanisms, pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals, 14 : 979-84.

[11] Celli BR,Fabbri LM,Aaron SD,Agusti A,Brook RD,Criner GJ .2023 .Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting: best practice. Am J Resp Crit Care Med, 207 : 1134-44.

[12] Todoroff CM,Berry MJ CM .2023 .Body Composition, Physical Function and Exercise Capacity in Chronic Obstructive Pulmonary Disease. J COPD, 20 : 256-61.

[13] Thu PN,Huong MN,Thi NT,Thanh HN,Minh KP .2021 .Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial. BMC Infect Dis, 21 : 1-8.

[14] Zhai C,Wang F,Xu R,Sun X,Ma W,Wang L .2024 .Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials. Postgrad Med J, 100 : 721-729.

[15] Chen D,Long H,Li S,Chen Y. .2024 .Interpretation of global strategy for the diagnosis, treatment, management and prevention of chronic obstructive pulmonary disease 2024 report. Chinese Gen Pract, 27 : 1533-9.

[16] Watz H,Kirsten AM,Ludwig-Sengpiel A,Krüll M,Mroz RM,Georges G .2024 .Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial. Resp Res, 25 : 378-84.

[17] Xiang Y,Luo X .2024 .Extrapulmonary comorbidities associated with chronic obstructive pulmonary disease: A review. International J COPD, 31 : 567-78.

[18] Gayen SK,Zulty M,Criner GJ .2024 .Elevated pulmonary vascular resistance is associated with increased lung transplant waitlist mortality among patients with chronic obstructive pulmonary disease and pulmonary hypertension: a retrospective cohort analysis. Resp Res, 25 : 79-83.

[19] Ramachandran HJ,Oh JL,Cheong YK,Jiang Y,Teo JY,Seah CW .2023 .Barriers and facilitators to the adoption of digital health interventions for COPD management: a scoping review. Heart Lung, 59 : 117-27.

Citations

Downloads

Views